Partnerships for better neglected disease drug discovery and development: how have we fared?

Temmy Sunyoto

    Research output: Contribution to journalA1: Web of Science-articlepeer-review


    Introduction: In the field of neglected disease, mushrooming partnerships have changed the landscape in the last decades. With high diversity in participants, type, scope, and operational models, partnership becomes the ultimate choice for drug discovery and development. This paper aims to reflect on this phenomenon based on experiences and lessons learned, providing insights for the future. Areas covered: Lack of safe and effective drugs for neglected diseases stems from market and public policy failure. Combining resources, skills, and expertise justifies working collaboratively in the R&D quest. The advancement of public-private partnerships (PPP), including product development partnership (PDP) for neglected diseases, is described, herein, including the rationale behind their conception, evolution, expansion, and alternative approaches. The author also discusses the appeals and the pitfalls of partnership in this field. Expert opinion: The progressive partnerships in drug discovery and development for neglected diseases need to be encouraged, especially in alignment with an open science culture. Experiences in partnerships vary with bias for successful ones, rendering more rigorous evaluation and research necessary. Eventually, the focus of improving partnership should not only be on addressing discovery bottlenecks, but also safeguarding access and delivery. Expanding focus to include vaccines and diagnostics is necessary.

    Original languageEnglish
    JournalExpert Opinion on Drug Discovery
    Issue number5
    Pages (from-to)531-537
    Number of pages7
    Publication statusPublished - 2020


    • Public-private partnership
    • product development partnership
    • neglected diseases
    • access
    • innovation
    • 21ST-CENTURY
    • HEALTH
    • MARKET


    Dive into the research topics of 'Partnerships for better neglected disease drug discovery and development: how have we fared?'. Together they form a unique fingerprint.

    Cite this